



Pharmaids Pharmaceuticals Limited

Date: 12.02.2026

To
The Corporate Relation Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001

Dear Sir / Madam,

Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018

Subject: Outcome of Board Meeting held on February 12, 2026

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation to our intimation dated February 09, 2026 regarding the Notice of the Board Meeting, the Board of Directors of the Company in their Meeting held today i.e., Thursday, February 12, 2026, have, inter alia considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors for the quarter and nine months ended December 31, 2025.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, a copy of results along with Limited Review Report thereon is enclosed herewith.

The Financial Results are also available on the website of the Company at www.pharmaids.com and on the website of BSE www.bseindia.com

The Board Meeting commenced at 04:15 P.M. and concluded at 05:00 P.M.

Kindly take the same on your record and oblige.

For Pharmaids Pharmaceuticals Limited

Prasanna
Subramanya Bhat

Digitally signed by Prasanna
Subramanya Bhat
Date: 2026.02.12 19:35:03
+05'30'

**Prasanna Subramanya Bhat
(Company Secretary & Compliance Officer)**

PHARMAIDS PHARMACEUTICALS LIMITED (CIN: L52520KA1989PLC173979)

Registered Office: Unit #201, Brigade Rubix, 20/14, HMT Factory Road, Peenya Plantation, Bangalore 560013 INDIA
Phone: 080-49784319 Email: compliance@pharmaids.com WEB: www.pharmaids.com

Independent Auditor's Review Report on unaudited quarterly standalone financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors of
Pharmaids Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited financial results of Pharmaids Pharmaceuticals Limited ("the Company") for the quarter and nine months ended 31st December 2025 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").


This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PPKG & Co.
Chartered Accountants

(Firm's Registration No. 0096558)


Giridhari Lal Toshniwal
(Partner)

(Membership No. 205140)

UDIN: 26205140ECEOPH1308



Place: Hyderabad
Date: 12th February 2026

PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Statement of Unaudited Standalone Financial Results for the Quarter and Nine months ended 31st December, 2025

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended	Quarter ended	Quarter ended	Nine months ended	Nine months ended	Year ended
	Dec 31, 2025	Sep 30, 2025	Dec 31, 2024	Dec 31, 2025	Dec 31, 2024	Mar 31, 2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Income						
Revenue from operations	83.28	596.55	120.79	791.36	220.84	234.09
Other income	6.09	19.07	0.38	59.88	1.21	101.89
Total income	89.37	615.61	121.17	851.24	222.04	335.98
Expenses						
Cost of materials consumed	33.17	928.75	0.01	1,019.39	0.01	3.01
Purchase of stock-in-trade	-	-	80.35	39.60	163.55	186.55
Changes in inventories of finished goods and work-in-progress	87.16	(276.78)	25.53	(180.32)	22.93	11.43
Employee benefits expense	154.69	159.86	86.66	454.30	232.33	341.82
Finance costs	57.17	101.95	6.99	270.18	9.54	214.91
Depreciation and amortisation expense	5.36	5.65	4.96	16.10	14.70	19.95
Other expenses	175.57	242.61	101.18	771.31	259.58	417.03
Total expenses	513.12	1,162.05	305.68	2,390.58	702.64	1,194.68
Profit/ (Loss) before exceptional items and tax	(423.75)	(546.43)	(184.51)	(1,539.34)	(480.59)	(858.70)
Exceptional items	-	313.05	-	313.08	-	-
Profit/ (Loss) before tax	(423.75)	(233.38)	(184.51)	(1,226.26)	(480.59)	(858.70)
Tax expense						
Current tax	-	-	-	-	-	-
Deferred tax	(112.77)	(68.15)	(25.22)	(313.75)	(58.31)	(130.78)
Total Tax Expense	(112.77)	(68.15)	(25.22)	(313.75)	(58.31)	(130.78)
Profit/ (Loss) for the year	(310.98)	(165.23)	(159.29)	(912.51)	(422.28)	(727.92)
Other comprehensive income						



PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Statement of Unaudited Standalone Financial Results for the Quarter and Nine months ended 31st December, 2025

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended	Quarter ended	Quarter ended	Nine months ended	Nine months ended	Year ended
	Dec 31, 2025	Sep 30, 2025	Dec 31, 2024	Dec 31, 2025	Dec 31, 2024	Mar 31, 2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
(i) Items that will not be reclassified subsequently to profit or loss						
Re-measurement on defined benefit plans and equity instruments	0.24	0.24	-	0.71	-	0.95
Income tax effect	(0.06)	(0.06)	-	(0.19)	-	(0.25)
(ii) Items that will be reclassified subsequently to profit or loss						
Effective portion of gains/(losses) on hedging instrument in cash flow hedges	-	-	-	-	-	-
Income tax effect	-	-	-	-	-	-
Other comprehensive income for the year, net of taxes	0.18	0.18	-	0.53	-	0.70
Total comprehensive income for the year	(310.80)	(165.06)	(159.29)	(911.98)	(422.28)	(727.22)
Paid-up Equity share capital (Face value Rs. 10/- per share)	3,526.78	3,526.78	3,526.78	3,526.78	3,526.78	3,526.78
Other Equity (excluding revaluation reserve)						2,852.10
Earnings per equity share						
Basic (in Rs)	(0.88)	(0.47)	(0.45)	(2.59)	(1.20)	(2.06)
Diluted (in Rs)	(0.88)	(0.47)	(0.45)	(2.59)	(1.20)	(2.06)

Place: Bengaluru

Date: 12-02-2026

By the order of the Board of Directors

For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthy

Whole Time Director

DIN : 00021699



PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Statement of Unaudited Standalone Financial Results for the Quarter and Nine months ended 31st December, 2025

Notes to Accounts:

1. The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at its respective meetings held on February 12, 2026.
2. The unaudited standalone financials results of the company have been prepared in accordance with the Ind AS as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act 2013 read with rule 3 of the Companies (Indian Accounting Standard) Rules 2015 (as amended) and in accordance with the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
3. The company operates in a single segment of providing Contract Research and Manufacturing Services.
4. The figures for the previous periods have been regrouped / reclassified wherever considered necessary.
5. The company decided to discontinue the lease agreement with Koye Lifesciences Private Limited with effect from December 01, 2025.

Place: Bengaluru

Date: 12-02-2026

**By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited**



Venu Madhava Kaparthy

Whole Time Director

DIN : 00021699



Independent Auditor's Review Report on consolidated unaudited quarterly financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors,
Pharmaids Pharmaceuticals Limited (Holding Company)

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Pharmaids Pharmaceuticals Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its subsidiaries for the quarter and nine months ended 31st December 2025 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
 - i. Adita Bio Sys Private Limited
 - ii. Siri Labvivo Diet Private Limited (step down subsidiary)
 - iii. Spring Labs (step down subsidiary)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the


aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of 2 subsidiaries included in the consolidated unaudited financial results, whose interim financial information / financial results reflect total revenues of Rs. 459.71 lakhs and Rs. 1,278.49 lakhs, total netprofit/(loss) after tax of Rs. (46.38) lakhs and Rs. (179.79) lakhs and total comprehensive income/(loss) of Rs. (48.11) lakhs and Rs. (175.60) lakhs for the quarter and nine months ended 31st December 2025, respectively as considered in the Statement.

These interim financial statements / financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Consolidated Financial Statement is not modified in respect of the above matters.

For PPKG & Co.
Chartered Accountants
(Firm's Registration No. 009655S)



Giridhari Lal Toshniwal
(Partner)
(Membership No. 205140)
UDIN:



Place: Hyderabad
Date: 12th February 2026

PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Statement of Unaudited Consolidated Financial Results for the Quarter and Nine months ended 31st December, 2025

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended	Quarter ended	Quarter ended	Nine months ended	Nine months ended	Year ended
	Dec 31, 2025	Sep 30, 2025	Dec 31, 2024	Dec 31, 2025	Dec 31, 2024	Mar 31, 2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Income						
Revenue from operations	543.00	860.50	470.93	2,069.85	1,467.93	1,944.74
Other income	7.60	7.36	0.73	18.96	3.00	10.40
Total income	550.60	867.85	471.66	2,088.82	1,470.93	1,955.14
Expenses						
Cost of materials consumed	106.88	983.97	207.92	1,334.25	754.08	932.44
Purchase of stock-in-trade	42.78	45.18	99.01	196.02	242.83	314.06
Changes in inventories of finished goods and work-in-progress	85.12	(274.10)	(4.28)	(189.86)	68.60	36.33
Employee benefits expense	328.28	318.09	324.80	1,065.12	911.06	1,316.24
Finance costs	71.79	92.86	48.46	284.20	108.05	208.76
Depreciation and amortisation expense	47.61	46.75	63.89	154.98	181.96	244.02
Other expenses	230.35	319.60	131.96	984.20	376.33	621.44
Total expenses	912.81	1,532.35	871.76	3,828.90	2,642.90	3,673.29
Profit/ (Loss) before exceptional items and tax	(362.21)	(664.50)	(400.09)	(1,740.08)	(1,171.97)	(1,718.15)
Exceptional items	(39.94)	295.30	(1.19)	255.40	(15.76)	(9.78)
Profit/ (Loss) before tax	(402.15)	(369.20)	(401.28)	(1,484.69)	(1,187.73)	(1,727.93)
Tax expense						
Current tax	-	-	-	-	-	-
Tax paid for earlier years	-	-	5.91	-	6.29	6.29
Deferred tax	(137.55)	(112.88)	(105.75)	(435.99)	(323.81)	(383.70)
Total Tax Expense	(137.55)	(112.88)	(99.83)	(435.99)	(317.53)	(377.41)
Profit/ (Loss) for the year	(264.60)	(256.31)	(301.45)	(1,048.70)	(870.21)	(1,350.51)
Other comprehensive income						
(i) Items that will not be reclassified subsequently to profit or loss						
Re-measurement on defined benefit plans and equity instruments	2.58	2.58	-	6.28	-	2.19
Income tax effect	(0.67)	(0.67)	-	(1.55)	-	(0.15)
(ii) Items that will be reclassified subsequently to profit or loss						
Effective portion of gains/(losses) on hedging instrument in cash flow hedges	-	-	0.01	-	0.01	-
Income tax effect	-	-	-	-	-	-
Other comprehensive income for the year, net of taxes	1.91	1.91	0.01	4.72	0.01	2.05
Total comprehensive income for the year	(262.69)	(254.40)	(301.44)	(1,043.98)	(870.20)	(1,348.47)



PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Statement of Unaudited Consolidated Financial Results for the Quarter and Nine months ended 31st December, 2025

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended	Quarter ended	Quarter ended	Nine months ended	Nine months ended	Year ended
	Dec 31, 2025	Sep 30, 2025	Dec 31, 2024	Dec 31, 2025	Dec 31, 2024	Mar 31, 2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Profit/ (Loss) attributable to:						
Equity holders of the Holding company	(247.88)	(251.52)	(193.34)	(990.79)	(683.78)	(1,077.66)
Non-controlling interest	(16.72)	(4.79)	(108.10)	(57.90)	(186.43)	(272.85)
Profit/ (Loss) for the year	(264.60)	(256.31)	(301.45)	(1,048.70)	(870.21)	(1,350.51)
Other comprehensive income attributable to:						
Equity holders of the Holding company	1.91	1.91	0.01	4.71	0.01	2.04
Non-controlling interest	0.00	0.00	0.00	0.01	0.00	0.01
Other comprehensive income for the year	1.91	1.91	0.01	4.72	0.01	2.05
Total comprehensive income attributable to:						
Equity holders of the Holding company	(245.97)	(249.61)	(193.34)	(986.08)	(683.78)	(1,075.62)
Non-controlling interest	(16.72)	(4.79)	(108.10)	(57.90)	(186.43)	(272.84)
Total comprehensive income for the year	(262.69)	(254.40)	(301.44)	(1,043.98)	(870.20)	(1,348.47)
Paid-up Equity share capital (Face value Rs. 10/- per share)	3,526.78	3,526.78	3,526.78	3,526.78	3,526.78	3,526.78
Other Equity (excluding revaluation reserve)						2,405.25
Earnings per equity share						
Basic (in Rs)	(0.70)	(0.71)	(0.55)	(2.80)	(0.73)	(3.05)
Diluted (in Rs)	(0.70)	(0.71)	(0.55)	(2.80)	(0.73)	(3.05)

Place: Bengaluru

Date: 12-02-2026

**By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited**

Venu Madhava Kaparthy
Whole Time Director
DIN : 00021699



PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.
Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com


Statement of Unaudited Consolidated Financial Results for the Quarter and Nine months ended 31st December, 2025

Notes to Accounts:

1. The Unaudited Consolidated Financial Results of Pharmaids(The Holding Company) and its subsidiaries (together referred to as Group) have been prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and relevant amendment rules thereafter and in accordance with the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. The Consolidated Financial Results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Holding Company at their respective Meetings held on February 12, 2026.
3. The group operates in a single segment of providing Contract Research and Manufacturing Services.
4. The figures for the previous periods have been regrouped / reclassified wherever considered necessary.
5. The holding company decided to discontinue the lease agreement with Koye Lifesciences Private Limited with effect from December 01, 2025.

Place: Bengaluru
Date: 12-02-2026

**By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited**



Venu Madhava Kaparthy
Whole Time Director
DIN : 00021699

